Evidence map›Paper›PMID 40548715›Full record

ArticleAntimicrobial agents and chemotherapy2025

Synthetic host defense peptide inhibits SARS-CoV-2 replication

Rhodri Harfoot, Blair Lawley, Leonor C Hernández, Joanna Kuang, Francesca R Hills, Shubhra Sinha, Margot J M Allais, Tom W Bird, Cody P Hird, John A Taylor and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rhodri HarfootDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Blair LawleyDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Leonor C HernándezDepartment of Pediatric Dentistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Joanna KuangDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Francesca R HillsDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Shubhra SinhaDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Margot J M AllaisDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Tom W BirdSchool of Biomedical Sciences, Victoria University of Wellington, Wellington, New Zealand.ORCID 0000-0003-3346-0444
Cody P HirdDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, London, Ontario, Canada.
John A TaylorSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.
Mihnea BostinaDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.ORCID 0000-0003-3621-3772
Davide ComolettiSchool of Biomedical Sciences, Victoria University of Wellington, Wellington, New Zealand.
Evan F HaneyCentre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.
Robert E W HancockCentre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-5989-8503
Daniel PletzerDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.ORCID 0000-0001-5750-7505
Miguel E Quiñones-MateuDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, London, Ontario, Canada.ORCID 0000-0001-9170-5601

Funding

CIHR FDN-15428Ministry of Business, Innovation and EmploymentMinistry of Health, New ZealandWestern Research Chair in Viral Pathogenesis
6 · The paper itself

Abstract

Although myriads of potential antiviral agents have been tested against SARS-CoV-2, only a handful have proven to be effective in clinical trials. During the COVID-19 pandemic, many known or novel peptides were evaluated for their ability to inhibit SARS-CoV-2 replication; however, testing of D-enantiomers that resist body and viral proteases has been limited. Here, we characterized the ability of D-3006, a D-enantiomeric synthetic host defense peptide, to inhibit SARS-CoV-2 replication

Indexed as

Antimicrobial Cationic PeptidesAntiviral AgentsSARS-CoV-2Virus ReplicationAdenosine MonophosphateAlanineAnimalsChlorocebus aethiopsCOVID-19COVID-19 Drug TreatmentHEK293 CellsHumansSpike Glycoprotein, CoronavirusVero CellsVirus InternalizationAdenosine MonophosphateAlanineAntimicrobial Cationic PeptidesAntiviral AgentsremdesivirSpike Glycoprotein, CoronavirusantiviralCOVID-19host defense peptidesinfluenza virusSARS-CoV-2

Identifiers

PMID40548715
PMCPMC12326988

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.